Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)

Long‐term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review

“…The 24 (38.5%) patients with metastasis received palliative care (Table ). The majority of patients with inoperable SCC received gemcitabine and cisplatin, either alone or in combination, as a first‐line treatment (Table ) . A total of eight cases in the metastasis group were excluded from the survival analysis because of insufficient information.…”

“…For pancreatic adenocarcinoma, there is now irrefutable evidence that adjuvant chemotherapy improves both overall and disease‐free survival and that gemcitabine is the gold standard adjuvant drug . For other squamous cell cancers, such as of the esophagus, adjuvant chemotherapy is not systematically recommended but may be indicated based on poor prognostic factors such as incomplete resection .…”

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines

“…Prior to these two studies mentioned above, no phase III study had demonstrated the benefits of neoadjuvant therapy for patients with resectable pancreatic cancer [7,8]; therefore, Japanese guidelines had not recommended neoadjuvant therapy for patients with pancreatic cancer until recently [9,10]; the same is true of guidelines in other countries overseas, which still do not recommend neoadjuvant therapy as standard treatment for patients with resectable pancreatic cancer with exceptions for those with high-risk factors [11][12][13][14]. Based on the results of the Prep-02/JSAP-05 study, however, the latest Japanese guidelines (Clinical Practice Guidelines for Pancreatic Cancer 2019) recommend gemcitabine plus S-1 combination therapy (GS therapy) as a standard neoadjuvant therapy for patients with resectable pancreatic cancer [15,16].…”

“…For patients with borderline resectable pancreatic cancer, Japanese guidelines recommend neoadjuvant therapy, in general, but have refrained from recommending any specific regimens [15,16]. Although guidelines in many other countries also recommend neoadjuvant therapy for borderline resectable pancreatic cancer, no consensus on any standard regimens has been established in any country until date [11][12][13][14]. Among the several ongoing randomized-controlled trials of treatments for borderline resectable pancreatic cancer (Table 2) [19][20][21][22][23][24][25][26][27], a phase II/ III study of neoadjuvant therapy with gemcitabine plus nab-paclitaxel therapy versus chemoradiotherapy with S-1 is under way in Japan; this study is expected to provide specific new evidence for the establishment of a standard regimen for borderline resectable pancreatic cancer [21].…”

Response to Preoperative Therapy in Localized Pancreatic Cancer

“…No clinical trial has yet definitively clarified which therapeutic modalities are most effective as preoperative therapy for PDAC between chemotherapy, (chemo)radiation, or novel agents, and how and when each modality should be administered to maximize patient's survival and quality of life while minimizing morbidity. Therefore, current guidelines have predominantly relied upon relatively low-level data (4,23).…”